Goldman Sachs Suggests Buying Calls on Johnson & Johnson

Goldman Sachs is out with a research report this morning, where it suggests that traders buy calls on Johnson & Johnson MON ahead of several drug catalysts. Goldman Sachs Pharma analyst, Jami Rubin, rates shares Buy and sees 14% upside to her 12-month price target of $77. The analysts believe JNJ options are not be pricing in the strong upside potential to shares around potential stock moving drug catalysts. Goldman Sachs suggests buying the June $67.50 call for $0.57. Johnson & Johnson is a holding company. The company and its subsidiaries are engaged in the research and development, manufacture and sale of a range of products in the health care field. It has more than 250 operating companies conducting business worldwide.